Effect of Tacrolimus on Vitiligo in Absence of UV Radiation Exposure

Sardana, Kabir

doi:10.1001/archderm.143.1.119

Cited by 11 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it has been suggested that UVR treatment is not necessary to achieve repigmentation with tacrolimus (Sardana et al., 2007), excimer laser has been claimed to enhance the pigmentary response (Ostovari et al., 2006). Pimecrolimus has also been successfully used in vitiligo although sometimes with conflicting results (Day and Lin, 2008) .…”

Section: Medical Therapymentioning

confidence: 99%

“…In addition, proliferation of both melanocytes and melanoblasts, as well as significantly enhanced stem cell factor (SCF) in vitro, and metalloproteinase-9 (MMP-9) activity -which is involved in cell migration-occur with tacrolimus-treated keratinocyte supernatants; these findings suggest the effects of tacrolimus on melanocyte growth and migration during repigmentation (Kang and Choi, 2006;Lan et al, 2005). Although it has been suggested that UVR treatment is not necessary to achieve repigmentation with tacrolimus (Sardana et al, 2007), excimer laser has been claimed to enhance the pigmentary response (Ostovari et al, 2006). Pimecrolimus has also been successfully used in vitiligo although sometimes with conflicting results (Day and Lin, 2008).…”

Section: Immunomodulatorsmentioning

confidence: 99%

See 1 more Smart Citation

Update on skin repigmentation therapies in vitiligo

Falabella

Barona

2009

Pigment Cell Melanoma Res

137

121

View full text Add to dashboard Cite

SummaryTreatment for vitiligo is difficult and prolonged. Nevertheless, at present considerable knowledge accumulated during several decades on the pathogenic mechanisms, revealed important clues for designing new strategies to improve vitiligo depigmentation. With available medical therapies, high repigmentation percentages mostly on facial and neck lesions are achieved, although they are less effective on trunk and limbs and poor on the acral parts of the extremities. Narrow band UVB and psoralens and UVA are the two most important treatments for generalized vitiligo affecting more than 10-20% of the cutaneous surface, and topical corticosteroids, or calcineurin inhibitors are the most valuable treatments for localized vitiligo. Persistence of achieved regimentation is variable and an undefined percentage of patients may have variable recurrence.When vitiligo becomes refractory, surgical methods may improve depigmentation as effectively as with medical therapy; in segmental (unilateral) or long standing, non-segmental (bilateral) stable vitiligo, repigmentation with surgical methods is usually permanent.

show abstract

Section: Medical Therapymentioning

confidence: 99%

Section: Immunomodulatorsmentioning

confidence: 99%

Update on skin repigmentation therapies in vitiligo

Falabella

Barona

2009

Pigment Cell Melanoma Res

137

121

View full text Add to dashboard Cite

show abstract

“…In Asia, Sardana et al. 11 reported the effects of tacrolimus in the absence of UV radiation in India. Our study is the first prospective study in Chinese with more patients enrolled.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo

Lo¹,

Cheng

Huang

et al. 2010

The Journal of Dermatology

View full text Add to dashboard Cite

Vitiligo is a common acquired idiopathic hypomelanotic disorder characterized by circumscribed depigmented maculae. The conventional treatments are limited by their inconsistent and incomplete responses, relapse rate, inconvenience to apply, side-effects and especially long-term effects. The aim of the present study was to determine the efficacy and safety of topical tacrolimus as monotherapy for the treatment of face/neck vitiligo in Taiwan. This was a multicenter, open-label, non-comparative study. Patients were at least 16 years old and had vitiligo lesions with Vitiligo Index of Disease Activity score +1 or more on face or neck. Patients received a monotherapy with 0.1% of tacrolimus ointment twice daily for 12 weeks. The efficacy was measured by the percentage of repigmentation of target lesion, which was graded as minimal (1-25%), mild (26-50%), moderate (51-75%) or excellent (76-100%). Patients who had at least mild repigmentation were defined as responders. A total of 61 patients were enrolled in this investigation. Most of the patients showed repigmentation at week 4. At the end of treatment, all patients showed repigmentation and 45.9% of patients were responders. During the study, 15 adverse events related to the ointment were reported. All the reported adverse events were mild and similar to the well-known adverse effect of tacrolimus in the treatment of atopic dermatitis. Tacrolimus ointment is effective and well tolerated for the treatment of patients with vitiligo in Taiwan. It will be another drug of choice for persons with vitiligo who are unable to receive regular phototherapy and fear the side-effects of topical steroid in long-term use.

show abstract

“…FK506, which is widely used to treat vitiligo, can trigger both diffuse (Sardana et al., ) and follicular (Silverberg et al., ) repigmentation. To cure vitiligo, cells must not only exhibit increased melanogenesis, they must also obtain the absolute ability to migrate/invade through the extracellular matrix of the skin.…”

Section: Introductionmentioning

confidence: 99%

FK506 positively regulates the migratory potential of melanocyte‐derived cells by enhancing syndecan‐2 expression

Jung

2016

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

Although topical tacrolimus (FK506) is known to promote repigmentation by increasing the pigmentation and migration of melanocytes, the mechanism through which FK506 regulates cell migration remains unclear. Here, we report that FK506 treatment enhanced cell spreading on laminin-332 and increased migration in both melanocytes and melanoma cells. Interestingly, FK506 also increased the expression of syndecan-2, a transmembrane heparan sulfate proteoglycan through c-jun terminal kinase activation. Moreover, siRNA-mediated reduction of syndecan-2 expression decreased FK506-mediated cell spreading and migration in melanoma cells and decreased focal adhesion kinase phosphorylation in both melanocytes and melanoma cells. Consistent with these effects on syndecan-2 expression, FK506 enhanced the membrane and melanosome localizations of PKCβII, a regulator of tyrosinase activity. This suggests that FK506 may play a dual regulatory role by affecting both melanogenesis and migration in melanocyte-derived cells. Interestingly, however, FK506 failed to show any synergistic effect on the migration of UVB-treated melanocyte-derived cells. Taken together, these data indicate that FK506 regulates cell migration by enhancing syndecan-2 expression, further suggesting that syndecan-2 could be a potential target for the treatment of patients with vitiligo.

show abstract

Effect of Tacrolimus on Vitiligo in Absence of UV Radiation Exposure

Cited by 11 publications

References 5 publications

Update on skin repigmentation therapies in vitiligo

Update on skin repigmentation therapies in vitiligo

Efficacy and safety of topical tacrolimus for the treatment of face and neck vitiligo

FK506 positively regulates the migratory potential of melanocyte‐derived cells by enhancing syndecan‐2 expression

Contact Info

Product

Resources

About